摘要
目的探讨接受免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗的肺癌患者外周血淋巴细胞亚群预测免疫相关不良事件(immune-related adverse events,irAEs)的价值。方法选取2022年1月至2024年10月接受ICIs治疗的肺癌患者,根据是否发生irAEs分为irAEs组(19例)和非irAEs组(38例)。采用流式细胞术检测两组患者治疗前后外周血淋巴细胞亚群,包括CD4^(+)T及CD8^(+)淋巴细胞、CD4^(+)/CD8^(+)比值、B细胞、NK细胞等,并进行统计学分析。结果4周期免疫治疗后,irAEs组CD8^(+)T比例低于非irAEs组(P<0.05)。irAEs组CD8^(+)淋巴细胞显著下降(P<0.05),而非irAEs组无明显变化,且CD8^(+)淋巴细胞比例明显升高(P<0.01)。非irAEs组4周期免疫治疗后CD4^(+)/CD8^(+)比值明显下降(P<0.01),而irAEs组无明显变化(P<0.05)。两组B淋巴细胞在免疫治疗后均出现下降,但非irAEs组下降更明显,且B淋巴细胞比例明显减低(P<0.01)。结论外周血淋巴细胞亚群在肺癌患者ICIs治疗后的变化具有预测irAE的潜在价值,可为临床个体化治疗提供参考依据。
Objective To explore the value of peripheral blood lymphocyte subsets in predicting immune related adverse events(irAEs)in lung cancer patients treated with immune checkpoint inhibitors(ICIs).Methods Lung cancer patients who received ICIs treatment from January,2022 to October,2024 were selected and divided into irAEs group(19 cases)and non-irAEs group(38 cases)based on whether irAEs occurred.Flow cytometry technique was used to detect peripheral blood lymphocyte subsets,including CD4^(+)and CD8^(+)T lymphocytes,CD4^(+)/CD8^(+)ratio,B cells,and NK cells in two groups of patients before and after treatment.The statistical analysis was conducted with results.Results After 4 cycles of immunotherapy,the CD8^(+)ratio in the irAEs group was lower than that in the non-irAEs group(P<0.05).CD8^(+)T lymphocytes significantly decreased in the irAEs group(P<0.05),while there was no significant change in the non-irAEs group,and the proportion of CD8^(+)T lymphocytes significantly increased(P<0.01).The CD4^(+)/CD8^(+)ratio in the non-irAEs group decreased significantly(P<0.01),while there was no significant change in the irAEs group(P>0.05).Both groups of B lymphocytes showed a decrease after immunotherapy,but the non-irAEs group showed a more significant decrease,and the proportion of B lymphocytes was significantly reduced(P<0.01).Conclusion The changes in peripheral blood lymphocyte subsets after ICIs treatment in lung cancer patients have potential value in predicting irAEs and can provide references for individualized clinical treatment.
作者
黄爱本
刘佳
张杜超
庞莉
谢梅
马西栋
马晓蓉
张振宁
钱进
江宏
薛新颖
潘磊
HUANG Aiben;LIU Jia;ZHANG Duchao;PANG Li;XIE Mei;MA Xidong;MA Xiaorong;ZHANG Zhenning;QIAN Jin;JIANG Hong;XUE Xinxin;PAN Lei(Department of Respiratory and Critical Care Medicine,Emergency Critical Care Medicine Center,Beijing Millennium Temple Hospital,Capital Medical University,Beijing 100038,China)
出处
《标记免疫分析与临床》
2025年第5期889-893,共5页
Labeled Immunoassays and Clinical Medicine
基金
首都医科大学优秀人才项目(编号:A2310)。
关键词
肺癌
免疫检查点抑制剂
免疫相关不良事件
外周血淋巴细胞亚群
Lung cancer
Immune checkpoint inhibitors
Immune related adverse events
Peripheral blood lymphocyte subsets
